Pfizer and BioNTech get positive results in phase 2/3 trial of COVID-19 Vax for children 5 to 11 years

Pfizer and BioNTech get positive results in phase 2/3 trial of COVID-19 Vax for children 5 to 11 years Trial results provide a strong foundation for seeking authorization of the vaccine for children 5 to 11 years old. The clinical trial data of COVID vaccine will be submitted to regulatory authorities for school-aged children before the start of the winter season https://ift.tt/eA8V8J